SAVE TIME AND MONEY WITH EARLIER QT ASSESSMENT

Save millions in Thorough QT study costs and shorten time-to-market by assessing the safety of your compound in Phase 1.

Imprecise reads may lead to an adverse drug warning label or poor decisions. Power your study with 10x more data and add value to your asset by leveraging actionable QT data earlier in clinical development. Get more info below, or download the infographic here. Then, contact us to schedule time to discuss your upcoming trial, or learn more about how we can help here.

Infographic_CS_EPQT_2018

Minimize Uncertainty and Risk in Your Clinical Trials